NCT00764387
Completed
Phase 4
Contrast-enhanced MRI Examination of Cerebral Neoplastic Enhancing Lesions: Comparison of Diagnostic Efficacy of Gd-DOTA 0.5M and Gadobutrol 1.0 M at 0.1 mmol/kg Body Weight: Intraindividual Comparison Clinical Study.
ConditionsNeoplastic CNS Lesions
Overview
- Phase
- Phase 4
- Intervention
- Gadovist® (Gadobutrol, BAY86-4875)
- Conditions
- Neoplastic CNS Lesions
- Sponsor
- Bayer
- Enrollment
- 166
- Primary Endpoint
- The primary analysis will be the comparison of the enhancements characteristics of Gadobutrol and Gd-TOTA on a lesion per lesion basis.
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Study to compare of two contrast agents in imaging brain lesions.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Known neoplastic CNS lesions
Exclusion Criteria
- Not provided
Arms & Interventions
Arm 1
Intervention: Gadovist® (Gadobutrol, BAY86-4875)
Arm 2
Intervention: Dotarem
Outcomes
Primary Outcomes
The primary analysis will be the comparison of the enhancements characteristics of Gadobutrol and Gd-TOTA on a lesion per lesion basis.
Time Frame: October 2007 to November 2008
Similar Trials
Active, not recruiting
Phase 1
Contrast-enhanced MRI examination of cerebral neoplastic enhancing lesions: comparison of diagnostic efficacy of Gd-DOTA 0.5 M and gadobutrol 1.0 M at 0.1 mmol Gd/kg body weight: Intra-individual comparison clinical study - NDEUCTR2007-005693-31-ITBAYER
Terminated
Not Applicable
Imaging Multiple Sclerosis Lesions Using Magnevist and GadavistMultiple SclerosisNCT01836055Wayne State University19
Completed
Phase 3
Multihance Versus Magnevist in Breast MRIBreast CancerNCT00486473Bracco Diagnostics, Inc130
Completed
Phase 2
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)Peripheral Arterial Disease (PAD)NCT00707876AMAG Pharmaceuticals, Inc.119
Terminated
Phase 2
CEST- Glucose Enhanced MRI for Metastatic Brain TumoursBrain Neoplasms, MalignantMetastasisNCT02796729British Columbia Cancer Agency3